Connect with us


Pfizer vaccine 100% effective in kids – Study



PFIZER and BioNTech today announced that their COVID-19 vaccine was 100 per cent effective in preventing infections in 12 to 15   year olds.

 Explaining the period measured from seven days to four months after administration of the second dose of the vaccine, CEO and co-founder of BioNTech, Ugur Sahin said the new data — a longer-term analysis of a Phase 3 trial conducted in 2,228 participants — will form the basis of an application to the Food and Drug Administration for an extension of their COVID-19 vaccine licence to cover youths in the age group.

“These are the first and only disclosed longer-term data demonstrating the safety and efficacy of COVID-19 vaccine in individuals 12 to 15 years of age.

  The growing body of data we have compiled from clinical trials and real-world surveillance to date strengthen the base of evidence supporting the strong efficacy,” he said.

The longer-term analysis of the Phase 3 trial data showed no serious safety concerns over a follow-up period of at least six months after the second dose of the vaccine.

Pfizer’s chairman and CEO, Albert Bourla, also said the additional data provides further confidence in vaccine’s safety and effectiveness profile in adolescents.

“This is especially important as we see rates of COVID-19 climbing in this age group in some regions, while vaccine uptake has slowed,” he said in the statement.

It will be recalled that the vaccine has been in use in this age group since May, when the FDA extended the emergency use authorisation for the vaccine to cover 12 to 15 year olds. In August, the vaccine, which the companies market under the name Comirnaty, was the first of COVID vaccines to receive a full licence for individuals, 16 years of age and older. 

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *